Lipid and Atherosclerosis Forum
Identifying and Addressing Unmet Clinical Needs
Monday, 4th December 2023
(Day 1)
| This meeting is for health care professionals and it is not open for members of the public. | ||
| The meeting has been fully organised by the UK Lipid and Atherosclerosis Forum team/Manchester University Hospitals NHS Foundation Trust and endorsed by HEART UK. Amarin, Amgen, Amryt, Daiichi-Sankyo, Novartis, LINC Medial and Ultragenyx have sponsored the event and have had no input or influence into the agenda, content, or selection of speakers of this meeting. | ||
| 12:00 | Registration and Lunch | |
| 13:20 | Opening and welcome | Professor Handrean Soran |
| SESSION 1 | Chairpersons: Prof Anne-Marie Kelly and Dr Ahai Luvai | |
| 13:30 | Data from France's HoFH register. | Professor Eric Buckert |
| 13:50 | Lp(a) in atherosclerosis and familial hypercholesterolaemia. | Professor Paul Durrington |
| 14:10 | Lipoprotein (a) as a therapeutic target: Current and future options. | Professor Ioanna Gouni-Berthold |
| 14:30 | International challenges for cardiovascular disease prevention. | Professor David Wood |
| 14:50 | Q&A | |
| 15:10 | Coffee | |
| 15:40 | SESSION 2 | Chairpersons: Dr Moulinath Banerjee and Dr Timothy Morris |
| 15:45 | Managing patients with HoFH: Current therapies. | Dr Michael France |
| 16:05 | Recommendation from the latest EAS HoFH statement and the role of new therapies. | Professor Eric Buckert |
| 16:25 | Familial Hypercholestrolaemia: Do we have a robust national plan? | Professor Anthony Wierzbicki |
| 16:45 | Nutraceuticals role in lipid lowering therapy: A review of efficacy and evidence. | Dr Peter Penson |
| 17:05 | Q&A | |
| 17:25 | Close Day 1 | |
| 18:15 | Speakers and Chairpersons meeting in the Lobby | |
| 18:30 | Transport to the Restaurant | |
| 19:00 | Speakers and Chairpersons Dinner | |
| 10:00 | Transport back to the hotel | |
| Sponsors: Amarin, Amgen, Amryt, Daiichi-Sankyo, Novartis, LINC Medial and Ultragenyx . |
Tuesday, 5th December 2023
(Day 2)
| This meeting is for health care professionals and it is not open for members of the public. | ||
| The meeting has been fully organised by the UK Lipid and Atherosclerosis Forum team/Manchester University Hospitals NHS Foundation Trust and endorsed by HEART UK. Amarin, Amgen, Amryt, Daiichi-Sankyo, Novartis, LINC Medial and Ultragenyx have sponsored the event and have had no input or influence into the agenda, content, or selection of speakers of this meeting. | ||
| 0830 | Registration and coffee | |
| 0850 | Welcome | Professor Handrean Soran |
| 09:00 | SESSION 3 | Chairs: Dr Peter Elton and Dr Maryam Ferdousi |
| 09:05 | Hypertension: An update on recent clinical guidelines and therapeutic options. | Professor Anthony Heagerty |
| 09:30 | Obesity and insulin resistance as cardiometabolic risk factors. | Dr Jan Ho |
| 09:50 | Impact of Bariatric surgery on lipoproteins quality and functional obesity. | Dr Safwaan Adam |
| 10:10 | New medical therapies for weight reduction and their impact on cardiometabolic risk in patients with diabesity. | Professor Akheel Syed |
| 10:30 | Managing ASCVD risk in patients with type 1 diabetes. | Dr Jonathan Scofield |
| 10:50 | Q&A | |
| 11:10 | Coffee | |
| 11:40 | Session 4 | Chairs: Dr Ian Menown and Dr Naresh Kanumilli |
| 11:45 | Disrupting the care of cardiovascular disease with single-course gene editing medicines. | Dr Scott Vafai. |
| 12:05 | Current and future lipid modification therapy targets. | Professor Paul Durrington |
| 12:25 | From high-intensity statins to high-intensity lipid-lowering therapy. | Professor Lluis Masana |
| 12:45 | An overview of omega 3 fatty acids and their role in clinical practice. | Professor Gabriel Steg |
| 13:05 | Inflammation and Cardiovascular disease. An update on clinical trials. | Professor Peter Libby |
| 13:25 | Q&A | |
| 13:45 | Lunch | |
| 14:30 | Session 5 | Chairs: Dr Hannah Delaney and Dr Charlotte Dawson |
| 14:35 | Natural history of FCS and unmet clinical needs: Data from UK FCS register. | Dr Paul Downie |
| 15:00 | MAFLD/NAFLD and ASCVD: Lessons from Human Genetics. | Professor Stefano Romeo |
| 15:20 | Demystifying genetics of severe hypertriglyceridaemia. | Professor Robert Hegele |
| 15:40 | Current and future therapies for Severe Hypertriglyceridemia and FCS. | Professor Handrean Soran |
| 16:00 | TBC | TBC |
| 16:20 | Q&A | |
| 16:40 | Final remarks and close | Professor Handrean Soran |
| Sponsors: Amarin, Amgen, Amryt, Daiichi-Sankyo, Novartis, LINC Medial and Ultragenyx. |